Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720472 | 1.00 | AR (0.48) | ARPGR | |
| SCHEMBL17722453 | 1.00 | AR (0.48) | ARPGR | |
| SCHEMBL332535 | 0.78 | AR (0.55) | ARPGR | |
| SCHEMBL332262 | 0.78 | AR (0.55) | ARPGR | |
| SCHEMBL333429 | 0.78 | AR (0.55) | ARPGR | |
| SCHEMBL333430 | 0.78 | AR (0.55) | ARPGR | |
| SCHEMBL332652 | 0.78 | AR (0.55) | ARPGR | |
| SCHEMBL1720400 | 0.76 | AR (0.48) | ARPGR | |
| SCHEMBL10075679 | 0.76 | AR (0.48) | ARPGR | |
| SCHEMBL22675196 | 0.73 | AR (0.47) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626036-B2 | 4-(3a-Methyl-1,3-dioxo-5-trifluoromethyl-3a,4-dihydro-3H-1l4-thia-2,6,6a-triaza-pentalen-2-yl)-2-trifluoromethyl-benzonitrile; anticarcinogenic agents; prostate glands; benign prostatic hyperplasia; alopecia; eating disorders; mammary glands; acne; AIDS; cachexia; male contraceptives; sexual disorders | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-01 | — | — | US | claimed |
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, FSHR | AR 1/4885PGR 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.